Linda McMurray, APRN
Family · Rutland, VTNPI 1093323610
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 47 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations. 2024 is the largest year on record at $345, 2.5 times the $140 reported in 2021.
Across 47 payments — averaging $17.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$160
- Corcept Therapeutics$120
- AstraZeneca$120
- Lilly USA, LLC$48
- Pfizer$48
- Exact Sciences$47
- plus $276 from 10 others
What the payments were for
- Food & beverage$819100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 10 | $160 |
| Corcept Therapeutics | 8 | $120 |
| AstraZeneca | 7 | $120 |
| Lilly USA, LLC | 2 | $48 |
| Pfizer | 2 | $48 |
| Exact Sciences | 3 | $47 |
| Idorsia Pharmaceuticals US Inc | 2 | $42 |
| Boehringer Ingelheim | 2 | $38 |
| Medtronic | 2 | $36 |
| Amgen | 2 | $32 |
| Astellas Pharma US Inc | 2 | $29 |
| Abiomed | 1 | $24 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Shield Therapeutics Inc | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Nestle Healthcare Nutrition Inc. | 1 | $15 |
How this compares
$819 in reported general payments places this provider in the 80th percentile of 75 family providers in Vermont.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 28 | $34,319 |
| EliquisApixaban | 32 | $29,114 |
| OzempicSemaglutide | 19 | $21,177 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $3,975 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 16 | $1,769 |
| LevemirInsulin Detemir | 14 | $1,746 |
| Levothyroxine Sodium | 188 | $1,630 |
| Atorvastatin Calcium | 153 | $1,529 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 59 | $1,508 |
| Omeprazole | 81 | $1,464 |
| Doxepin Hcl | 11 | $1,283 |
| Pantoprazole Sodium | 74 | $1,269 |
| Rosuvastatin Calcium | 100 | $1,070 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $742 |
| Gabapentin | 48 | $708 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $38 | $34,31928 claims |
| PfizerEliquis | $48 | $29,11432 claims |
| Novo NordiskOzempic, Levemir | $160 | $22,92333 claims |
| AstraZenecaSymbicort | $120 | $3,97511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 75 family providers in Vermont.
Other family in Rutland
- Kristen SheehanRutland$4K
- Alyssa BrownRutland$3K
- Kayla CummingsRutland$432
- Kimberly EugairRutland$46
- Rachel GuyVergennes$36K
- Cheryl McNeilSouth Burlington$2K
- Penny BrusoShaftsbury$2K
- Catherine FaldutoBurlington$2K
- Katelyn EmmettBurlington$2K
- Hannah PrevostSt Johnsbury$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.